[{"id":"ef2d8abd-fb23-45a9-a65d-be237a4a3a82","acronym":"","url":"https://clinicaltrials.gov/study/NCT02515630","created_at":"2021-01-20T23:56:21.590Z","updated_at":"2024-07-02T16:35:45.372Z","phase":"Phase 2","brief_title":"Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","source_id_and_acronym":"NCT02515630","lead_sponsor":"Sierra Oncology LLC - a GSK company","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojjaara (momelotinib)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/29/2016","start_date":" 01/29/2016","primary_txt":" Primary completion: 07/18/2017","primary_completion_date":" 07/18/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2023-06-19"}]